MorphoSys AG: MorphoSys Reports Preliminary Q3 2022 Monjuvi

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year

Related Keywords

Germany , Boston , Massachusetts , United States , Canada , United Kingdom , Planegg , Bayern , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Morphosys Agview , Exchange Commission , Linkedin , Xencor Inc , Twitter , Drug Administration , Updates Financial Guidance , Product Sales , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys , Reports , Reliminary , 022 , Monjuvi , Sales , Updates , Financial , Guidance ,